Zacks Investment Research
25 Jun 2026, 14:55 UTC · 20w ago
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Impact · against what's priced in
Natera's first PMDA approval for Signatera in Japan creates a new geographic revenue stream and a regulatory foothold for subsequent cancer type submissions. While the initial stock jump reflects the milestone, long-term value depends on upcoming pricing and reimbursement decisions.
- NTRA+0.60
No priced-in read yet
- In context
The PMDA approval for colorectal cancer makes Signatera the first approved MRD test in Japan, opening a significant new market and providing a pathway for further expansion into bladder cancer.
Read from the article alone

Search tags




